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What’s Known
•
People
reporting
long-term
symptoms associated with COVID-19,
(Long
COVID
Syndrome),
have
complained of various problems,
including respiratory, cardiovascular,
musculoskeletal,
and
neurological
problems. However, the extent and
characteristics of such post-acute phase
lingering symptoms are not clear yet.

What’s New
•
Long COVID syndrome (LCS)
is a frequent and significant and at
times, disabling condition. In this large
population-based study, we reported
that LCS has significant associations
with sex (more observed in women),
respiratory symptoms at the onset,
and the severity of the illness (length of
hospital stay).
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Abstract

Background: Recently, people have recognized the post-acute
phase symptoms of the COVID-19. We investigated the longterm symptoms associated with COVID-19, (Long COVID
Syndrome), and the risk factors associated with it.
Methods: This was a retrospective observational study. All the
consecutive adult patients referred to the healthcare facilities
anywhere in Fars province from 19 February 2020 until 20
November 2020 were included. All the patients had a confirmed
COVID-19 diagnosis. In a phone call to the patients, at least
three months after their discharge from the hospital, we obtained
their current information. The IBM SPSS Statistics (version
25.0) was used. Pearson Chi square, Fisher’s exact test, t test,
and binary logistic regression analysis model were employed. A
P value of less than 0.05 was considered to be significant.
Results: In total, 4,681 patients were studied, 2915 of whom
(62.3%) reported symptoms. The most common symptoms
of long COVID syndrome were fatigue, exercise intolerance,
walking intolerance, muscle pain, and shortness of breath.
Women were more likely to experience long-term COVID
syndrome than men (Odds Ratio: 1,268; 95% Confidence
Interval: 1,122-1,432; P=0.0001), which was significant.
Presentation with respiratory problems at the onset of illness was
also significantly associated with long COVID syndrome (Odds
Ratio: 1.425; 95% Confidence Interval: 1.177-1.724; P=0.0001).
A shorter length of hospital stay was inversely associated with
long COVID syndrome (Odds Ratio: 0.953; 95% Confidence
Interval: 0.941-0.965; P=0.0001).
Conclusion: Long COVID syndrome is a frequent and disabling
condition and has significant associations with sex (female),
respiratory symptoms at the onset, and the severity of the illness.
Please cite this article as: Asadi-Pooya AA, Akbari A, Emami A, Lotfi M,
Rostamihosseinkhani M, Nemati H, Barzegar Z, Kabiri M, Zeraatpisheh Z, FarjoudKouhanjani M, Jafari A, Sasannia F, Ashrafi S, Nazeri M, Nasiri S, Shahisavandi
M. Risk Factors Associated with Long COVID Syndrome: A Retrospective Study.
Iran J Med Sci. 2021;46(6):428-436. doi: 10.30476/ijms.2021.92080.2326
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Introduction
It has been more than a year since the start of the coronavirus
disease-2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome (SARS)-coronavirus-2 (SARS-CoV-2).
During the early stages of the pandemic, people were mainly
concerned with its fatality, and later on, everybody noticed the
psychosocial consequences of the pandemic. More recently,
people have recognized the post-acute phase lingering symptoms
of the disease.1, 2 Many COVID-19 survivors have reported a
Iran J Med Sci November 2021; Vol 46 No 6
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variety of persistent signs and symptoms after
the acute phase of the illness.3
Although there is no universally accepted
terminology and definition for this condition,
some authors have considered the persistence
of symptoms (fatigue, breathlessness, cough,
joint pain, chest pain, muscle aches, headache,
and several others, which could not be attributed
to any other cause) beyond two weeks for mild
disease, beyond four weeks for moderate to
severe illness, and beyond six weeks for critically
ill patients as “long COVID syndrome” (LCS).4
The National Institute for Health and Clinical
Excellence (NICE), the Scottish Intercollegiate
Guidelines Network (SIGN), and the Royal
College of General Practitioners (RCGP) have
jointly developed the following definitions: a.
ongoing symptomatic COVID-19: signs and
symptoms of COVID-19 from 4 to 12 weeks
and b. post-COVID-19 syndrome: signs and
symptoms developed during or after an infection
consistent with COVID-19, which continue for
more than 12 weeks and are not explained
through an alternative diagnosis.5
The etiology and the biological underpinnings
of LCS are not clear yet. However, SARS-CoV-2
invades many tissues and has multi-organ
and multi-system impacts.6 In addition, the
persistence of viremia and psychological factors
may also contribute to the development of LCS.7, 8
People reporting long-term symptoms associated
with COVID-19 have complained of various
problems, including respiratory, cardiovascular,
musculoskeletal, and neurological problems.9-12
Meanwhile, the extent, characteristics, and the
associated factors of such post-acute phase
lingering symptoms are not entirely clear yet.
In the current population-based study, we
investigated the full spectrum of symptoms
of patients suffering from LCS (based on the
literature review and consultations with experts
in the field). We also examined the chronicity of
the symptoms to add to the existing literature.
Finally, we scrutinized the potential risk factors
associated with the development of LCS in
a large cohort of patients with documented
COVID-19 to add to the existing literature.
Methods
Participants
In this retrospective, uncontrolled, and
observational cohort work, all the consecutive
adult patients, 18 years or older, were referred
and admitted to healthcare facilities (55 centers)
throughout Fars province (located in the South
of Iran with a population of 4,851,000 people)
from February19, 2020 to November 20, 2020.
Iran J Med Sci November 2021; Vol 46 No 6

The Shiraz University of Medical Sciences
Institutional Review Board approved this study
(IR.SUMS.Rec.1399.022). All the participants
consented orally: (We conduct the research to
investigate the lingering symptoms of the COVID19. Do you agree to participate in this study and
answer our questions over the phone?).
All the patients had a confirmed COVID-19
diagnosis with a positive result on Real-Time
polymerase chain reaction (PCR) testing of
nasopharyngeal and oropharyngeal samples. All
the samples were taken at the emergency room.
Data Collection
For each patient, admitted with a diagnosis of
COVID-19, the following data were collected at
the emergency room by the admitting physician
and entered into a database (on admission):
age, sex, presence of fever, cough, respiratory
distress, muscle pain, change in mental status,
loss of smell, dizziness, headache, abdominal
pain, nausea, vomiting, and anorexia. Other
collected data included: PCR test results and
admission to a hospital ward [COVID-specific
ward, intensive care unit (ICU), or others].
Underlying chronic health problems such as
renal, liver, cardiac, or neurological, and diabetes
mellitus (DM), cancer, hypertension (HTN), and
pulmonary disorders were also collected (selfdeclared). No data were available about the
hospital course of the patients (laboratory test
results, management, complications). However,
the outcome was also recorded in the database,
as dead or discharged. The diagnosis dates of
the patients were from 19 February 19, 2020 to
November 20, 2020. In a telephone conversation
with the discharged patients, made by the last 12
authors, at least three months after their illness
(from March 1 to 14, 2021), we investigated
their current health status and obtained their
information, if they agreed to participate and
answer the questions (consented orally: We are
conducting research to investigate the lingering
symptoms of the COVID-19. Do you agree to
participate in this study and answer our questions
over the phone?). We randomly selected every
other adult patient in our database (alternate
patients in the database sorted by their phone
numbers). If someone did not answer, in the
second attempt, we selected the previous patient
in the list, who was skipped initially, because of
not responding. Figure 1 illustrates the inclusion
process of the participants.
A data gathering form (appendix 1) was
specifically designed for the purpose of data
collection, and all the team members were
instructed by the first author, on how to inquire
the data consistently and in the same manner.
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1. Total number of the patients: 13,165

2. Died in the hospital: 1,694

3. The target population: 11,471

4. Every other patient (even numbers) was
selected: 5,735

6. Refused to participate: 427
5. Patients contacted: 5,735

Below 18 years of age: 109
No response after the second call: 518

7. The included participants: 4,681

Figure 1: The figure shows the recruitment process of the
study.

The first part of the form (eight questions)
collected the demographic data and some
confirmatory data (date of admission and
underlying disorders before COVID-19) to crosscheck with the primary database. In the second
part (28 questions), we asked if the patient had
noticed any problems (cough, fatigue, muscle
or joint pain, and headache), or was suffering
from any conditions (chronic problems) in the
prior week compared with their pre-COVID-19
conditions (any symptoms, complaints, or
problems that they did not have before their
COVID-19 diagnosis, but appeared after the
illness and specifically during the past seven
days). The survey was designed and developed
as follows: We conducted a literature review and
numerous interviews with other participants. We
developed the items and conducted an expert
validation to assess the clarity and relevance of
the items with regard to the construct of interest.
For the purpose of this study, we defined LCS as
any symptoms, complaints, or problems that the
patients did not experience before their COVID19 diagnosis, but have persistently had during the
seven days prior to the follow-up. We specifically
asked their complaints during the past seven
days in order to minimize the risk of recall bias.
Since our work was a retrospective inquiry, we
did not study the starting date of the symptoms/
problems. We also asked the severity of their
complaints (1. Mild and tolerable; 2. Moderate; 3.
Severe and disabling). In the third part of the
430

questionnaire (five questions), we asked the
patients to compare their current status (on five
items) with their pre-COVID-19 status based
on a Likert scale (1. Much worse; 2. Somewhat
worse; 3. The same as before; 4; Somewhat
better; 5. Much better). The following were also
asked: 1. ability to perform the activity of daily
living; 2. concentration and mind workability ; 3.
studying and reading ability; 4. quality of life; 5.
hope for the future.
Statistical Analyses
The SPSS Statistics (IBM Corp., USA, version
25.0) was used. We arbitrarily categorized the
patients into two groups (to investigate the
longevity and chronicity of the symptoms): a.
Group 1: a phone call from three to six months
after being diagnosed with COVID-19; b. Group
2: a phone call from six to 12 months after the
illness. Values were presented as mean±SD for
continuous variables and as the number (percent)
of subjects for categorical variables. Based on
the previous studies, the following variables
were selected as the risk factors potentially
associated with long COVID syndrome: sex
(men and women), age (mean±SD), length of
hospital stay (mean±SD), respiratory problems
at the onset, neurological problems at the
onset, gastrointestinal problems at the onset,
pre-existing chronic medical problems, and
ICU admission. Pearson Chi square, Fisher’s
exact test, t test, Bonferroni correction test, and
binary logistic regression analysis model were
employed for statistical analyses, then significant
variables from univariate analyses were entered
into the logistic regression analysis model. Odds
ratios (ORs) and 95% confidence intervals (CIs)
were estimated. A P value (two-sided) of less
than 0.05 was considered to be significant.
Results
General Characteristic of the Patients
Since the start of the pandemic until November
20, 2020, 13,165 patients with confirmed COVID19 were referred to 55 healthcare facilities in
Fars province; 1694 people died (case fatality
rate: 12.8%) and 11,471 individuals (adults and
children) were discharged from the hospitals.
In the follow-up phase of this study, 4,681 adult
patients discharged from the hospitals agreed
to participate; 427 people (8.4%) of those, who
were contacted refused to participate in this
study (figure 1). The respondents included: 2634
patients (56%) and 2047 family members/caregivers (44%). The participants included 2478
men (52.9%) and 2203 women (47.1%), and their
mean age was 52±15 years.
Iran J Med Sci November 2021; Vol 46 No 6
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Clinical Characteristics of the Patients
Manifestations of COVID-19 on admission
were as follows: respiratory/pulmonary in 4182
(89.3%) [hypoxemia (SpO2<93% by Pulse
Oximeter reading) in 56.6%, respiratory distress
in 54.1%, cough in 52.8%, and chest pain in
5%]; neurological in 818 (17.5%) [headache
in 14.1%, loss of smell in 2.2%, change in
mental status in 1.7%, loss of taste in 1.1%];
and gastrointestinal (GI) in 731 (15.6%) patients
[nausea in 8.6%, vomiting in 5.1%, diarrhea in
4,9%, and abdominal pain in 3.2%]. Several
patients had non-specific manifestations [fever
in 41%, myalgia in 39.5%, anorexia in 10.9%,
and dizziness in 4%]. A minority [482 (10.3%)]
of the patients needed ICU admission. Duration
of the hospital stay was as short as a few hours
(in eight patients) to as long as 112 days, two
months or more in eight patients, (mean±SD:
7±6 days). In addition, 1766 patients (37.7%) had
pre-existing chronic medical conditions (19.9%
HTN, 16.1% DM, 10.6% cardiac problems,
2.6% asthma, 1.9% renal problems, 1.5% other
pulmonary disorders, and 1.2% cancer).
Long COVID Manifestations
We called 1996 (42.6%) patients, diagnosed
with COVID-19 six to 12 months prior, and
2685 (57.4%) people with the infection three to
six months prior. In total, 2915 (62.3%) people
Table 1: Long COVID symptoms/complaints
Clinical Manifestations
3-6 months follow-up, N=2685
n (%)
Weakness
543 (20%)
Muscle pain
562 (21%)
Joint pain
491 (18%)
Fatigue
847 (32%)
Sleep difficulty
453 (17%)
Shortness of breath
563 (21%)
Chest pain
303 (11%)
Palpitation
304 (11%)
Cough
272 (10%)
Excess sputum
171 (6%)
Loss of smell
123 (5%)
Loss of taste
78 (3%)
Sore throat
124 (5%)
Headache
316 (12%)
Dizziness
205 (8%)
Brain fog
319 (12%)
Excess sweating
232 (9%)
Exercise intolerance
694 (26%)
Walking intolerance
587 (22%)
Diarrhea
73 (3%)
Abdominal pain
88 (3%)
Anorexia
104 (4%)
Weight loss
251 (9%)
Weight gain
147 (5%)
After Bonferroni correction, the significant P value is at <0.002
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reported symptoms/complaints, 1774 (66%) had
shorter follow-ups and 1141 (57%) with longer
follow-ups (P=0.0001) had long-lasting problems.
Table 1 represents the symptoms/complaints
of the patients in these two groups. In general,
all the symptoms/complaints were reported by
both groups; however, some of the symptoms/
complaints were significantly less frequent
in those with an infection for a longer time
(weakness, muscle pain, fatigue, sleep difficulty,
palpitation, cough, brain fog, exercise, and
walking intolerance). Table 2 shows the severity
of the reported symptoms/complaints. While
most of the symptoms/complaints were rated as
mild and tolerable by the participants, a minority
of the patients reported severe and disabling
problems. There were no significant differences
between the two groups of the patients (those
diagnosed with COVID-19 from the previous six
to 12 months versus people with the infection
from the previous three to six months) with
respect to the severity of the symptoms of LCS
(table 3). Other reported chronic problems (not
mentioned in the tables) included: Hair loss in
102 (2%), new-onset DM in 18, new-onset HTN
in 11, loss of libido in two, and new-onset chronic
renal failure in one patient.
Factors Associated with Long COVID Syndrome
Table 4 reveals the factors associated with
6-12 months follow-up, N=1996
n (%)
278 (14%)
291 (15%)
296 (15%)
493 (25%)
254 (13%)
347 (17%)
175 (9%)
166 (8%)
139 (7%)
123 (6%)
92 (5%)
54 (3%)
74 (4%)
207 (10%)
125 (6%)
161 (8%)
149 (7%)
396 (20%)
315 (16%)
42 (2%)
56 (3%)
65 (3%)
130 (7%)
101 (5%)

P value
0.0001
0.0001
0.002
0.0001
0.0001
0.003
0.005
0.001
0.0001
0.808
0.944
0.722
0.142
0.146
0.083
0.0001
0.160
0.0001
0.0001
0.214
0.393
0.303
0.001
0.598
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Table 2: The severity of the reported symptoms/complaints of long COVID syndrome
Clinical Manifestations
Mild and Tolerable
Moderate
Severe and Incapacitating
n (%)
n(%)
n (%)
Weakness
552 (67%)
179 (22%)
89 (11%)
Muscle pain
551 (65%)
191 (23%)
106 (12%)
Joint pain
447 (57%)
228 (29%)
110 (14%)
Fatigue
900 (67%)
316 (24%)
117 (9%)
Sleep difficulty
397 (56%)
192 (27%)
117 (17%)
Shortness of breath
646 (71%)
194 (22%)
66 (7%)
Chest pain
346 (73%)
111 (23%)
20 (4%)
Palpitation
328 (70%)
107 (23%)
31 (7%)
Cough
312 (77%)
74 (18%)
22 (5%)
Excess sputum
192 (66%)
71 (24%)
29 (10%)
Loss of smell
135 (63%)
43 (20%)
37 (17%)
Loss of taste
75 (57%)
38 (29%)
18 (14%)
Sore throat
171 (86%)
25 (13%)
2 (1%)
Headache
327 (63%)
133 (25%)
62 (12%)
Dizziness
251 (76%)
56 (17%)
22 (7%)
Brain fog
306 (64%)
129 (27%)
45 (9%)
Excess sweating
205 (54%)
114 (30%)
62 (16%)
Exercise intolerance
600 (55%)
321 (29%)
169 (16%)
Walking intolerance
469 (53%)
271 (30%)
153 (17%)
Diarrhea
88 (79%)
16 (14%)
8 (7%)
Abdominal pain
97 (67%)
33 (23%)
14 (10%)
Anorexia
107 (64%)
43 (26%)
18 (10%)
1766 patients did not have long COVID syndrome
Table 3: Severe symptoms/complaints of the long COVID syndrome
Clinical Manifestations
3-6 months follow-up, N=2685
Weakness
56 (2%)
Muscle pain
68 (2.5%)
Joint pain
65 (2.5%)
Fatigue
74 (2.8%)
Sleep difficulty
86 (3.2%)
Shortness of breath
44 (1.6%)
Chest pain
13 (0.5%)
Palpitation
16 (0.6%)
Cough
10 (0.4%)
Excess sputum
19 (0.7%)
Loss of smell
21 (0.8%)
Loss of taste
11 (0.4%)
Sore throat
1 (0.03%)
Headache
40 (1.5%)
Dizziness
15 (0.6%)
Brain fog
32 (1.2%)
Excess sweating
35 (1.3%)
Exercise intolerance
120 (4.5%)
Walking intolerance
110 (4.1%)
Diarrhea
6 (0.2%)
Abdominal pain
11 (0.4%)
Anorexia
11 (0.4%)
After Bonferroni correction, the significant P value is at 0.002

any reported long COVID symptoms/complaints.
Long-term COVID symptoms/complaints were
significantly more frequent in women, those with
respiratory problems at the onset of infection,
those admitted to the ICU, and those with longer
hospital stays. We included these variables
432

6-12 months follow-up, N=1996
33 (1.7%)
38 (1.9%)
45 (2.3%)
43 (2.2%)
31 (1.6%)
22 (1.1%)
7 (0.4%)
15 (0.8%)
12 (0.6%)
10 (0.5%)
16 (0.8%)
7 (0.4%)
1 (0.05%)
22 (1.1%)
7 (0.4%)
13 (0.7%)
27 (1.4%)
49 (2.5%)
43 (2.2%)
2 (0.1%)
3 (0.2%)
7 (0.4%)

Missing data
15
11
13
12
10
12
10
10
13
11
11
13
12
14
14
18
19
12
23
26
22
23

P value
0.614
0.920
0.618
0.825
0.045
0.408
0.971
0.294
0.030
0.188
0.136
0.014
0.891
0.156
0.740
0.639
0.185
0.093
0.118
0.719
0.309
0.881

in a regression analysis model. Women had
LCS more frequently than men (OR: 1.268;
95% CI: 1.122-1.432; P=0.0001). Presentation
with respiratory problems at the onset was
also significantly associated with having LCS
(OR: 1.425; 95% CI: 1.177-1.724; P=0.0001).
Iran J Med Sci November 2021; Vol 46 No 6
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Table 4: Factors in association with reporting any long COVID symptoms/complaints in univariate analysis
Clinical Characteristics
Long COVID syndrome,
No chronic symptoms,
N=2915
N=1766
Sex (Female:Male)
1430:1485 (ratio: 0.96)
773:993 (ratio: 0.78)
Age (mean±SD), years
52±15
52±16
Length of hospital stay (mean±SD), days
7.7±6.8
6.1±5.3
Respiratory problems at onset
2647 (91%)
1535 (87%)
Neurological problems at onset
520 (18%)
298 (17%)
Gastrointestinal problems at onset
455 (16%)
276 (16%)
Pre-existing chronic medical problems
1105 (38%)
661 (37%)
ICU admission
344 (12%)
138 (8%)

Finally, a shorter length of hospital stay was
inversely correlated with having LCS (OR:
0.953; 95% CI: 0.941 to 0.965; P=0.0001). The
ICU admission was not significant (P=0.169).
The Big Picture
The patients rated the following items over
the past week compared with that of before
their COVID-19, as shown in table 5 (ability
to do routine and normal tasks; ability to
concentrate and think; ability to study; overall
quality of life; hope for the future). In the next
step, we categorized the above items as worse
(much worse+somewhat worse) versus not
(the same+somewhat better+much better),
and we evaluated the associations among
these variables and reported LCS. Table 6
demonstrates the results of these analyses.
The patients with chronic symptoms/complaints
(LCS) reported a worse status on all the items.
Discussion
Herein, we observed that long COVID syndrome
is a frequent and disabling condition and found

P value
0.0001
0.470
0.0001
0.0001
0.405
0.835
0.756
0.0001

that more than six in 10 patients with COVID19, who required hospitalization, had longlasting symptoms/complaints of LCS. The
demographic characteristics of our patients
(age, sex, length of hospital stay, and the need
for ICU admission) were comparable with those
from other studies.13-16 This suggests that our
data could be generalized to other populations.
Reports of long-lasting COVID-19 symptoms,
the so-called “long COVID syndrome (LCS)”, are
rising very fast and more should be known about
its prevalence and the associated risk factors.13
In a previous study of 4,182 patients with COVID19, the individuals self-reported their symptoms
prospectively in the COVID symptom study
application. A total of 558 (13.3%) participants
reported symptoms lasting ≥28 days, 189 (4.5%)
for ≥8 weeks, and 95 (2.3%) reported symptoms
for ≥12 weeks.13 In another study of 384 patients
(mean age 59.9 years; 62% male) followed for
a median of 54 days post-discharge, 53% of
the patients reported persistent breathlessness,
34% had cough, and 69% reported fatigue.14
In a study of 478 patients, 244 patients (51%)
declared at least one symptom that did not exist

Table 5: How would you rate the following items over the past week compared with that before your COVID-19?
Change of the following Much worse Somewhat worse The same as
Somewhat better Much better
items
n (%)
n (%)
before n (%)
n (%)
n (%)
Ability to do routine and
205 (4.4%)
758 (16.3%)
3619 (77.9%)
57 (1.2%)
8 (0.2%)
normal tasks
Ability to concentrate and 117 (2.5%)
634 (13.6%)
3869 (83.3%)
22 (0.5%)
4 (0.1%)
think
Ability to study
90 (1.9%)
427 (9.2%)
4097 (88.2%)
30 (0.6%)
3 (0.1%)
Overall quality of life
168 (3.6%)
634 (13.6%)
3781 (81.4%)
54 (1.2%)
9 (0.2%)
Hope for the future
176 (3.8%)
480 (10.3%)
3886 (83.7%)
75 (1.6%)
25 (0.5%)

Table 6: How would you rate the following items over the past week compared with that before your COVID-19?
Rated worse on the following items
Long COVID syndrome,
No chronic symptoms,
N=2915
N=1766
Ability to do routine and normal tasks
904 (31%)
59 (3%)
Ability to concentrate and think
701 (24%)
50 (3%)
Ability to study
477 (16%)
40 (2%)
Overall quality of life
765 (26%)
37 (2%)
Hope for the future
611 (21%)
45 (3%)
After Bonferroni correction, the significant P value is at <0.01
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Missing
data
34
35
34
35
39

P value
0.0001
0.0001
0.0001
0.0001
0.0001
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before COVID-19: Fatigue was reported by 31%,
cognitive symptoms were observed in 21%, and
new-onset dyspnea was reported in 16%.16 The
difference in the methodology may explain the
various rates of LCS reported in these studies,
while active inquiry suggests a prevalence of more
than 50%, observed in our study and the reports
by Morin and others, Mandal and colleagues, and
Jacobson and others, passive inquiry suggests a
much lower prevalence.14, 16, 17 It is likely that the
passive inquiry of the symptoms in people with
no LCS (with no fatigue, brain fog), the designed
app was used more frequently.13
The most common symptoms of LCS in
our study were fatigue (tiredness), exercise
intolerance, walking intolerance, muscle pain,
shortness of breath, and weakness (loss of
stamina). Fortunately, most of these symptoms
resolved in numerous people over time.
Unfortunately, all of these symptoms lasted
for many months (more than six months) in a
substantial number of people. Many of the observed
symptoms in our study were consistent with those
from previous studies.13, 14, 18, 19 Meanwhile, we
also reported some intriguing symptoms (e.g.,
palpitation, GI problems, and weight change) that
have less often been recognized before.
In the current study, we observed that the
female sex, initial respiratory symptoms, and
prolonged hospitalization were significantly
associated with experiencing LCS. In a previous
study, LCS was more likely correlated with
increasing age, body mass index, and female sex.
Experiencing more than five symptoms during
the first week of illness was also associated
with LCS (Odds Ratio:3.53).13 In another study
of 134 patients, 86% of the participants reported
at least one residual symptom at the follow-up.
The presence of symptoms at the follow-up was
not related to the severity of the acute COVID19 illness. Women were significantly more likely
to report residual symptoms.15 In a study of 599
patients, female sex, a proportional increase in
the number of symptoms at the onset of COVID19, and ICU admission were all the independent
risk factors for the post-COVID-19 syndrome.20
The reproduced observation that female sex
is more often associated with LCS is intriguing
and should be further explored in future studies.
Analysis of the pathophysiological drivers
underlying the female sex as a risk factor for
LCS is a critical next step.
Our
observation
that
prolonged
hospitalization was significantly associated
with experiencing LCS and the observations by
Sudre and colleagues and Peghin and others13, 20
that experiencing more symptoms during the
first week of illness was associated with LCS
434

may suggest that a more severe COVID-19
at presentation is a significant risk factor for
experiencing LCS. However, the study by Sykes
and others did not reach this conclusion.15
Speculatively, we can hypothesize that a more
severe COVID-19 is a risk factor for LCS on
account of two possibilities: first, severe COVID19 causes a more severe immune response and
cytokine storm and consequently more organ
damages (brain, lungs, heart).12, 21, 22 Second,
severe COVID-19 is usually aggressively treated
with more medications, corticosteroids and is
more often associated with iatrogenic harm,
due to intubation or nosocomial infections,
with long-lasting sequelae. Therefore, it is
reasonable to assume that LCS is a biological
phenomenon. Evidence suggests that sustained
endotheliopathy is common in convalescent
COVID-19, which may lead to long COVID
pathogenesis. Other possible mechanisms of
LCS may include an elevated inflammatory state,
cerebrovascular changes, peripheral organ
damage, and dysfunction.23-25 It is also plausible
to assume that LCS is the result of psychosocial
consequences of COVID-19, at least to some
extent and in some patients.26 While we could
not establish a cause and effect relationship, we
observed that LCS is significantly associated
with the impaired daily activity and quality of life
of the patients. These speculations should be
explored in future studies.
A major limitation of this study is that the data
set is entirely based on a phone consultation
with no clinical, psychological, or paraclinical
evaluations. Additionally, we likely have missed
some patients with a negative PCR test result,
who were diagnosed based on the typical
clinical and radiological signs of COVID-19. In
addition, the data on LCS were not collected
prospectively, and we could not provide the
information on their temporal relationship (start
date) with the illness (COVID-19), and the
course of the LCS symptoms/problems based
on the current study. Moreover, we did not
evaluate the asymptomatic infections and those
with a mild illness in this study. Furthermore, we
did not perform validity and reliability testing of
our questionnaire formally. Finally, our findings
were limited by the absence of a control group
and pre-COVID assessments in this cohort.
On the other hand, the strengths of our study
include a large sample size, a comprehensive
data collection form, and quality assessment of
the symptoms (self-declared).
Conclusion
Long COVID syndrome is a frequent and
Iran J Med Sci November 2021; Vol 46 No 6

Long COVID syndrome

significant and at times, disabling condition. In
this large population-based study, we report
that LCS has significant associations with sex
(women), respiratory symptoms at the onset, and
the severity of the illness (length of hospital stay).
The scientific community should investigate the
pathophysiology of this condition to discover the
biological underpinnings of LCS.
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